Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Hires at RainDance; DxInsights Names Knowlden Executive Director

Premium

RainDance Technologies this week said that Jay Therrien, Roger Schaller, and Yafei Liu have joined the company to further accelerate growth in the digital PCR and targeted sequencing markets.

Therrien joins RainDance as vice president of worldwide sales. He was previously senior vice president of global sales at Knome. Prior to this, he was vice president of commercial operations and sequencing at Life Technologies, and he has also worked in various sales roles at Illumina. Therrien holds a BS from the University of Illinois at Urbana-Champaign and a PhD from the University of Kansas.

Schaller will serve as RainDance's business leader for next-generation sequencing. He joins the company from Affymetrix, where he was senior director of business development for molecular diagnostics. Previously, he was director of North American sales and marketing at Cepheid, and he has also served in various business development, sales, and marketing positions at Dade-Behring. He holds a BS in medical technology and biology from Illinois State University.

Liu joins RainDance as head of commercial operations for the Asia-Pacific region. Prior to RainDance, he was responsible for Life Technologies' China sales team selling digital PCR, sequencing, and quantitative PCR products. Liu also previously worked at Applied Biosystems before it was acquired by Life Tech.


DxInsights, a non-profit, independent diagnostics education organization, has appointed Ethan Knowlden as executive director.

Knowlden was previously with Novartis Vaccines and Diagnostics, and most recently served as vice president, business development and licensing and corporate counsel for the diagnostics unit. He received a JD from the University of Virginia and BA from Wesleyan University.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.